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Abstract
Background: The accurate prediction of enzyme-substrate interaction energies is one of the
major challenges in computational biology. This study describes the improvement of protein-ligand
binding energy prediction by incorporating protein flexibility through the use of molecular dynamics
(MD) simulations.
Results: Docking experiments were undertaken using the program AutoDock for twenty-five
HIV-1 protease-inhibitor complexes determined by x-ray crystallography. Protein-rigid docking
without any dynamics produced a low correlation of 0.38 between the experimental and calculated
binding energies. Correlations improved significantly for all time scales of MD simulations of the
receptor-ligand complex. The highest correlation coefficient of 0.87 between the experimental and
calculated energies was obtained after 0.1 picoseconds of dynamics simulation.
Conclusion: Our results indicate that relaxation of protein complexes by MD simulation is useful
and necessary to obtain binding energies that are representative of the experimentally determined
values.
Background
The human immunodeficiency virus type 1 aspartic pro-
tease (HIV-1 PR) is an important enzyme due to its key
role in viral maturation. Inactivation of the enzyme causes
the production of immature, noninfectious viral particles.
The enzyme therefore is an attractive target in anti-AIDS
drug design, and the effect of binding various inhibitors
on the protease structure is currently the focus of intensive
research [1–3].
To obtain information about the position and energy of
binding between an inhibitor and the corresponding pro-
tein, several automated docking programs have been de-
veloped [4–6]. Given recent improvements in search
algorithms and energy functions, computational docking
methods have become a valuable tool to probe the inter-
action between an enzyme and its inhibitors. These meth-
ods can contribute significantly to the understanding of
structural and energetic basis of enzyme-substrate interac-
tions [7–9].
Protein-ligand docking methods aim to predict the bind-
ing energy of the protein-ligand complex given the atomic
coordinates. In such calculations, both the protein and
ligand can be treated as rigid bodies [10,11]; alternately,
the ligand, the protein, or both molecules, can be com-
pletely or partially flexible [12,13].
One advantage of incorporating flexibility is that it ena-
bles a search without bias introduced by the initial model.
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This bias normally influences both the orientation and
conformation of the ligand in the active site, which usual-
ly represents a local minimum conformation [14]. More
importantly, the lock and key concepts used to evaluate
enzyme-substrate binding, in reality, refer to flexible locks
and keys that are both in constant dynamic (thermal) mo-
tion [15]. For example, an analysis of conformational
changes upon complex formation for a representative set
of 39 pairs of ligand-free and ligand-bound structures
showed that 50% of these proteins undergo substantial
main-chain and side chain conformational changes when
the ligand is bound [15].
Several techniques have been developed to predict the
binding energies of HIV-1 protease-inhibitor complexes
[16–21]. Head RD et al., 1996 [16] used an approach that
calculates physicochemical properties of the ligands and
the receptor-ligand complexes to estimate the free energy
of binding. The enthalpy of binding is calculated by mo-
lecular mechanics, while properties such as complementa-
ry hydrophobic surface area are used to estimate the
entropy of binding through heuristics. Gohlke H et al.,
2000 [17] developed DrugScore, a knowledge-based scor-
ing function, to discriminate between well-docked ligand
binding modes and those largely deviating from the na-
tive structure.
Schapira M et al., 1999 [20] used the finite difference Pois-
son-Boltzmann implementation of the electrostatic term,
in conjunction with appropriate surface and entropy
terms to predict the binding energy of 13 HIV-1 protease-
inhibitor complexes. The predicted binding energies had
a correlation coefficient of 0.66 with the experimental da-
ta. Recently, Österberg F et al., 2002 used AutoDock 3.0, a
ligand flexible docking program, together with combining
21 protease structures into a single representative grid of
interaction energies for incorporating the side chain mo-
tion into a docking simulation protocol [21]. The correla-
tion coefficient between experimental and calculated
binding energies produced by this technique was 0.79.
Since most current docking programs treat the receptor
and/or ligand as rigid objects, this represents an impor-
tant cause of failure to predict the correct binding enzyme-
substrate energies [18]. We address this problem by per-
forming Molecular Dynamic (MD) simulations on HIV-1
protease-inhibitor complexed and using the resulting
structures to calculate the binding energies by AutoDock,
a ligand flexible docking program.
Results and discussion
Correlation between experimentally determined and cal-
culated binding energy
The primary objective of this study was to determine
whether protein relaxation would improve prediction of
protein-ligand binding energies. Table 1 shows that the
correlation coefficient of the experimentally determined
and calculated binding energies from AutoDock for the
twenty-five protease-inhibitor complexes after protein-
rigid docking was 0.38. The correlations after 0.01, 0.1, 1,
and 10 picoseconds (ps) of MD simulations were 0.53,
0.87, 0.79, and 0.74 respectively. These correlations are
plotted in Figure 1. One outlier (from 1hvi) was noticed
in Figure 1B; after it is eliminated, the correlation coeffi-
cient changes from 0.53 to 0.72 after 0.01 ps of
simulation.
All these correlations represent a significant improvement
over the protein-rigid docking results. The best results
were obtained from the structures at the 0.1 ps MD simu-
lation time point. These structures also have low (≅ 0.3 Å)
average all-atom root mean square deviations (RMSD)
relative to the experimental results. Table 2 shows the all-
atom RMSD between each simulated complex and the
corresponding protease-inhibitor x-ray structure. The av-
erage all-atom RMSD for the complexes increases from
0.18 Å at 0.01 ps to 2.92 Å at the end of 10 ps of simula-
tion time. Similar results are consistently observed regard-
less of the five starting seeds used in the MD simulations.
When a constant value of 6.5 is subtracted from the pre-
dicted energies after 0.1 ps MD, the binding energies of al-
most all of the predictions were within 2.0 kcal/mol of the
experimental values. Three complexes, 1hvi, 1hvr, and
1hte had poor predicted energies, with an average error of
4.34, 4.31, and 5.09 kcal/mol, respectively. Among these,
one (1hvi) had better predicted energies when compared
to the results of protein-rigid docking.
Influence of the protease flap movement on calculated 
binding energy
The beta-strand flap is the most flexible region in the HIV-
1 protease. It is normally 7 Å RMSD from the active site
and is in an open conformation in the native state [22,23].
The protease undergoes significant structural changes on
binding to an inhibitor. The two flaps fold over the inhib-
itor to form a tunnel-shaped active site and are held in this
close position by hydrogen bonding from Ile50 and Ile50'
NH groups of the enzyme to a water molecule, which in
turn is hydrogen bonded to the P2 and P1' CO groups of
the inhibitor [24]. The bonding stabilizes the flaps in a
closed position and inhibits the activities of the enzyme.
MD simulation has been used to study the movement of
the flap region of HIV-1 protease with a ligand [25–30].
The flaps initially opened to an all-atom RMSD of 25 Å
within 200 ps and became completely open at the end of
a 10 ns simulation. In this study (Figure 2), the flaps
opened up and moved away from the x-ray structure from
0.54 Å at 0.1 ps to 3.30 Å RMSD at 10 ps (the flap RMSDBMC Structural Biology 2003, 3 http://www.biomedcentral.com/1472-6807/3/2
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was calculated from residue 40 to 60 of each protein
chain). These movements, after 0.1 ps of simulation, are
inversely correlated with the quality of the binding energy
prediction. As shown in Table 1, the correlation coeffi-
cient significantly decreased from 0.87 at 0.1 ps to 0.74 at
10 ps as the all-atom flap RMSD increased from 0.54 to
3.30 at 0.1 and 10 ps, respectively.
Complementarity between the ligand and the binding site
is the basic concept behind ligand binding. This is mani-
fest as steric complementarity, i.e. the shape of the ligand
is mirrored in the shape of the binding site, allowing mo-
lecular interactions between two molecules [31]. MD sim-
ulations allow rearrangement of the protease side chain,
especially on the active site surface, which improves the
interacting surface complementarities of the complex. As
shown in Table 2, after 0.1 ps, the time scale that pro-
duced the best correlation coefficient, the average all-
atom RMSD of the complex was only 0.35 Å, while the av-
erage all-atom RMSD of the flap region was 0.54 Å.
Influence of MD simulation duration on ligand binding
Ligand docking revealed a consistent set of recurring bind-
ing modes. For all MD time scales, well-clustered docking
results could be obtained. Generally, the lowest binding
energy clusters are associated with the lowest all-atom
RMSDs of the ligands. The best results in terms of lowest
binding energy are located in a similar position of the x-
Figure 1
Plots of experimentally-determined and calculated binding energies for the twenty-five HIV-1 protease-inhibitor complexes. 
The correlation coefficient improves from 0.38 without any MD simulation (A), to 0.53 at 0.01 ps of MD simulation (B), peak-
ing at 0.87 after 0.1 ps (C), and dropping off to 0.79 at longer time scales of to 1 ps or more (D).BMC Structural Biology 2003, 3 http://www.biomedcentral.com/1472-6807/3/2
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ray structure at the active site. Table 3 shows the number
of docking solutions in a cluster (N) along with the all-
atom ligand RMSD for each MD time scale.
A small N value indicates strong specificity of binding,
with all of the solutions resembling one of only a small
number of binding conformations and orientations. On
the other hand, if N is large, the experiment indicates a
low specificity of binding, since the solutions are com-
posed of many different binding conformations or
orientations.
In this study, the clustering result of ligands had an aver-
age N of 10.72 for docking without any MD, 8.36, 4.12,
5.88, and 7.16 for docking with 0.01, 0.1, 1, and 10 ps
MD simulation, respectively. On average, the lower
number of docking solutions in the cluster for all MD sim-
ulation time scales indicates that the ligands bind to their
binding pocket with high specificity. The docked ligands
after 10 ps MD simulation exhibited a wide range of
RMSDs (0.87 Å to 3.86 Å) with an average RMSD of 2.52
Å, which indicates the failure of the ligands to recognize
and specifically bind to the binding site with the protease
flaps open.
Conclusions
In this study, we illustrate the importance of taking dy-
namics into account to predict the structure and energetics
of protein-ligand interactions. It is clear that relaxation of
HIV-1 protease for 0.1 ps MD simulations is enough for
rearrangement of the surface-binding pocket to produce
good correlations between calculated and experimental
binding energies. The binding energies of all protease
molecules bound to different inhibitors were influenced
by the movement of the flap regions with the correlation
coefficient decreasing as the flaps moved away from the
experimental structure. The differences in these correla-
tions may reflect biological features of the dynamics of
HIV-1 protease-inhibitor complexes.
Future work with larger data sets, different energy func-
tions, different docking and binding energy evaluation
methods, and more starting seeds, is necessary to deter-
mine the optimal parameters to robustly predict protein-
substrate binding energies in silico.
Methods
A set of twenty-five HIV-1 protease-inhibitor complexes
with experimentally determined structures and binding
energies chosen from the Protein Data Bank (PDB), were
used in this study [32–50]. All complexes were
determined by x-ray crystallography with resolution and
R-factor less than 3.0 and 0.19, respectively. The PDB
codes of the complexes along with the experimental bind-
ing energies are listed in Table 1.
Figure 2
Superposition of the Cα traces of part of the HIV-1 protease x-ray structure 4phv before (dark line) and after (light line) 10 ps 
of MD simulation bound to the inhibitor (space-fill). The flap region (above the inhibitor) moved away from the x-ray structure 
during the simulation, with all-atom RMSDs of 0.54 Å at 0.1 ps, 0.95 Å at 1 ps and 3.30 Å at 10 ps, respectively. Generally, after 
0.1 ps, as the all-atom RMSD increased, the correlation coefficient of the experimentally-determined and calculated binding 
energies decreased.BMC Structural Biology 2003, 3 http://www.biomedcentral.com/1472-6807/3/2
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The experimental binding energies used in this study were
converted from the experimental inhibition constants
(Ki), using the equation:
∆G0 = -RT ln Ki
where ∆G0 is the Gibbs free energy of binding (kcal/mol),
R is the gas constant (1.987 cal K-1 mol-1) and T is the ab-
solute temperature (room temperature, 300 K). Assuming
that the Ki values of each complex were obtained under
the quasi-equilibrium conditions of Michaelis-Menton ki-
netics [51,52], we expect that a plot of ∆G0 against ln Ki is
a straight line, with a slope given by the thermal energy,
RT = 0.6 kcal/mol (at 300 K). Since the Ki values were de-
termined by different experimental techniques, some lev-
el of noise might exist in the underlying data. We expect
our method to behave robustly in this regard.
Molecular Dynamics simulations
MD simulations of all complexes were carried out with the
NAMD software version 2.5b1 [53] using the X-PLOR
force field [54]. Missing atoms in 1heg, 1hte and 5hvp
were added by using the guesscoord command in NAMD.
The van der Waals, bond, angle, dihedral, and improper
dihedral parameters for all the ligands were adopted from
the Hetero-compound Information Centre-Uppsala HIC-
Up http://xray.bmc.uu.se/hicup[55]. The water molecule
under the flaps present in all complexes was included in
all steps throughout this study except for 1hvr, where the
structural water was removed in the preparation of the
protease to be docked with the ligand (the ligand of 1hvr,
Table 1: Comparison of experimentally-determined and calculated binding energies for twenty-five HIV-1 protease-inhibitor 
complexes.
PDB code Resolution R-factor Experimental 
binding 
energy (kcal/
mol)
Calculated binding energy (kcal/mol) (picosecond time scales)
no MD 0.01 0.10 1.00 10.00
1gno 2.30 0.17 -9.40 -7.61 -16.01 -15.90 -12.13 -10.30
1hbv 2.30 0.18 -8.68 -10.46 -15.90 -14.85 -12.44 -10.64
1hef 2.20 0.16 -12.27 -13.96 -18.26 -19.81 -15.30 -12.32
1heg 2.20 0.19 -10.56 -9.15 -17.77 -19.41 -13.39 -11.16
1hih 2.30 0.19 -10.97 -9.50 -17.68 -17.35 -14.59 -11.95
1hiv 2.00 0.17 -12.27 -11.36 -23.25 -21.54 -19.68 -17.31
1hps 2.20 0.14 -12.57 -11.97 -20.08 -20.10 -16.98 -16.60
1hpv 1.90 0.19 -12.60 -13.88 -16.25 -20.77 -17.37 -16.48
1hvi 1.80 0.18 -13.74 -7.51 -10.91 -24.58 -15.45 -14.72
1hvj 2.00 0.16 -14.26 -10.19 -24.37 -23.58 -16.49 -14.81
1hvk 1.80 0.18 -13.79 -11.42 -20.42 -21.72 -17.92 -14.98
1hvl 1.80 0.19 -12.27 -9.36 -17.53 -21.48 -16.56 -13.87
1hvr 1.80 0.19 -12.96 -14.26 -23.94 -23.77 -19.33 -16.22
1hvs 2.25 0.15 -14.04 -7.98 -22.53 -18.69 -16.48 -14.55
1hte 2.80 0.16 -7.69 -7.86 -9.85 -9.10 -8.38 -7.74
1htf 2.20 0.19 -9.31 -8.31 -20.36 -15.89 -18.28 -18.87
1htg 2.00 0.19 -11.58 -12.06 -19.15 -19.95 -17.49 -15.64
1pro 1.80 0.19 -15.40 -11.52 -21.80 -21.91 -21.33 -21.32
1sbg 2.30 0.19 -10.56 -10.45 -16.96 -16.67 -13.86 -11.91
2upj 3.00 0.14 -10.10 -8.00 -15.90 -14.99 -11.74 -11.18
4phv 2.10 0.18 -12.51 -13.89 -22.45 -20.77 -17.37 -16.48
4hvp 2.30 0.18 -8.38 -9.72 -17.80 -14.48 -9.27 -8.80
5hvp 2.00 0.18 -8.12 -8.83 -17.46 -16.01 -9.29 -8.09
8hvp 2.50 0.14 -12.27 -8.62 -20.69 -20.16 -18.70 -16.15
9hvp 2.80 0.18 -11.38 -12.18 -20.88 -19.41 -18.88 -15.55
Correlation coefficient 0.38 0.53 0.87 0.79 0.74
For each complex, the PDB code, resolution, R-factor, the experimental energy, the lowest binding energy as evaluated by AutoDock before any 
MD simulation, and the lowest binding energy after MD simulation for four time points (0.01, 0.1, 1, and 10 ps) are shown. The bottom row shows 
the correlation coefficient between the experimental and calculated energies. Protein-rigid docking produced poor correlation (of 0.38) between 
the experimental and calculated energies, while the best correlations (of 0.87) were obtained after 0.1 ps MD simulations.BMC Structural Biology 2003, 3 http://www.biomedcentral.com/1472-6807/3/2
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which is a urea-based inhibitor, does not bind a water
molecule in this position). The water molecules were add-
ed to the binding site of 1hvs because all the water mole-
cules were absent in the experimental structure. Protein
protonation states were modeled as in the related HIV-1
protease MD simulation study [56]. All protein residues
were modeled in their charged state except for one of the
two aspartic acid groups (Asp 25 and Asp 25') in the active
site since previous studies [57–59] have shown that at
least one of these two aspartic acids is protonated. We
used a protonated Asp 25' and deprotonated Asp 25 for all
HIV-1 protease-ligand complexes. The terminal residues
of both monomers were also protonated (Pro 1, Pro 1',
Phe 99 and Phe 99').
The complexes were immersed in a 20 Å radius sphere of
TIP3-water using the program SOLVATE [60] to allow the
protein-ligand complexes to relax in an aqueous environ-
ment. One hundred steps of energy minimization of the
protein-ligand-water complex were initially performed,
followed by 10 ps MD simulation at 300 K, with an atom-
based shifted distance-dependent dielectric constant, ε =
4r; a switch function on van der Waals interaction, and a
time step of 1 femtosecond (fs). The nonbonded
interaction list was updated every 20 time steps. The van
der Waals interactions were truncated at a distance of 12
Å. The simulations were repeated with five different start-
ing seeds. The structures at 0.01 ps, 0.1 ps, 1 ps and 10 ps
were recorded and processed in the docking step.
Preparation of protease-inhibitor complexes
To calculate the binding energy with AutoDock, we first
prepared the protein complexes by separating each snap-
shot recorded from MD simulations into one file contain-
ing the protease and the water molecules, and one file
containing only the ligand. Polar hydrogens were then
Table 2: All-atom root mean square deviation (RMSD) of the protein-ligand complexes relative to their corresponding x-ray structures.
PDB code Complex all-atom RMSD (Å) (picosecond time scales)
0.01 0.10 1.00 10.00
1gno 0.22 0.32 1.11 3.20
1hbv 0.16 0.35 0.95 2.84
1hef 0.16 0.34 0.90 2.71
1heg 0.16 0.32 0.91 2.80
1hih 0.18 0.35 0.90 2.93
1hiv 0.20 0.36 0.85 2.98
1hps 0.18 0.38 0.95 2.95
1hpv 0.17 0.33 0.92 2.96
1hvi 0.14 0.35 0.92 2.99
1hvj 0.17 0.33 0.91 3.06
1hvk 0.12 0.33 0.94 2.97
1hvl 0.21 0.33 0.91 2.93
1hvr 0.18 0.36 0.92 2.92
1hvs 0.24 0.35 0.92 2.88
1hte 0.20 0.37 0.90 2.89
1htf 0.10 0.32 0.93 3.06
1htg 0.14 0.31 0.76 2.86
1pro 0.26 0.38 0.94 2.94
1sbg 0.20 0.36 0.93 2.86
2upj 0.23 0.41 0.90 2.88
4phv 0.14 0.35 0.90 2.93
4hvp 0.20 0.35 0.93 2.95
5hvp 0.18 0.31 0.94 2.93
8hvp 0.18 0.35 0.92 2.90
9hvp 0.19 0.35 0.92 2.90
Complex (average) 0.18 0.35 0.92 2.92
Flap (average) 0.14 0.54 0.95 3.30
The correlations between experimentally-determined and calculated binding energy significantly improved after MD simulation, and were inversely 
influenced by the all-atom RMSD of the complex as well as the protease flap region (i.e., as the all-atom RMSD increased with longer MD simula-
tions, the correlations were reduced from their peak). The best correlation of 0.87 was observed at 0.1 ps. Similar results were observed regard-
less of the starting seed used.BMC Structural Biology 2003, 3 http://www.biomedcentral.com/1472-6807/3/2
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added to the protein coordinates with the PROTONATE
utility from AMBER [61]. AMBER united atom force field
charges were assigned, and solvation parameters were
added using the ADDSOL utility. The 3D affinity grid
fields were created using the auxiliary program AutoGrid.
The center of protein mass was chosen as the grid center.
In this stage, the protein was embedded in the 3D grid and
a probe atom was placed at each grid point. The affinity
and electrostatic potential grid was calculated for each
type of atom in the protease molecule. The number of grid
points in x, y, z-axis was 60 × 110 × 60 with grid points
separated by 0.375 Å.
Ligands that had a peptide-like N- or C-terminal end were
assigned a charge. Hydrogen atoms were added to fill all
empty valences, and Kollman united-atom charges [62]
were also assigned to the ligands. Rotatable dihedrals in
the ligands were assigned using the program AutoTors and
were allowed to rotate freely. The nonpolar hydrogens
were removed and the partial charges from these were
added to the carbon that held the hydrogen. The atom
type for the aromatic carbons was reassigned to be han-
dled by the aromatic carbon grid map. These preparations
were done for each ligand using the AutoTors module.
Automated docking
Docking calculations were carried out using AutoDock,
version 3.0.5 [4]. Three binding energy terms were taken
into account in the docking step: the van der Waals inter-
action represented as a Lennard-Jones 12–6 dispersion/re-
pulsion term, the hydrogen bonding represented as a
directional 12–10 term, and the Coulombic electrostatic
potential.
Table 3: Ligand all-atom RMSD (Å) and the number of docking solutions (N) in the cluster from 100 Larmarckian genetic algorithm 
(LGA) docking runs of twenty-five protease-inhibitor complexes.
PDB No MD 0.01 ps 0.1 ps 1 ps 10 ps
code N RMSD (Å) N RMSD (Å) N RMSD (Å) N RMSD (Å) N RMSD (Å)
1gno 32 0.62 18 0.88 4 1.54 13 1.57 16 1.54
1 h b v42 . 1 581 . 1 861 . 3 062 . 0 593 . 1 8
1hef 8 1.46 6 1.24 4 1.13 12 2.14 9 2.23
1heg 15 2.16 7 0.88 4 0.94 6 1.31 5* 1.20
1hih 14 1.21 6 0.58 4 0.75 7 1.81 4 3.86
1hiv 12 1.27 8 1.04 4 1.06 5 1.29 7 2.75
1 h p s 1 0 1 . 0 351 . 3 510 . 9 551 . 5 322 . 8 4
1 h p v31 . 3 391 . 3 250 . 7 352 . 9 272 . 5 9
1hvi 13 1.53 6 0.93 4 0.95 2 2.94 5 3.54
1hvj 3 1.33 3 0.75 2 0.95 2 2.35 4 2.86
1hvk 8 1.44 4 1.34 7 1.12 9 0.97 2 3.26
1hvl 12 1.72 2 1.61 2 1.54 5 2.49 3 2.92
1hvr 18 0.98 9 0.70 6 0.68 8 1.01 8 2.37
1hvs 13 1.73 7 0.87 1 1.03 3 0.99 3 1.24
1hte 3 2.26 9 1.21 3 1.88 7 2.72 8* 3.23
1htf 13 1.11 8 1.03 6 0.93 13 2.11 10 2.9
1htg 8 1.96 9 0.97 8 1.03 6 0.96 12 2.86
1pro 18 0.76 15 0.78 7 0.77 9 0.63 9 0.87
1sbg 11 1.71 17 0.61 8 0.73 2 1.01 9 2.63
2upj 15 1.75 17 1.74 4 1.79 2 2.07 9 3.54
4 p h v12 . 9 391 . 5 731 . 2 332 . 5 173 . 0 8
4hvp 3 1.97 11 0.98 2 1.37 5 1.91 7 2.16
5hvp 12 1.89 5 0.86 2 0.88 8 0.97 8* 1.01
8hvp 13 1.75 5 1.53 2 1.41 2 2.25 8 2.16
9 h v p62 . 6 661 . 4 821 . 5 422 . 5 182 . 1 2
Average 10.72 1.63 8.36 1.10 4.12 1.13 5.88 1.80 7.16 2.51
Docking solutions with ligand all-atom RMSDs within 1.0 Å of each other were clustered together and ranked by the corresponding lowest energy 
representative. The lowest energy solution of the lowest ligand RMSD cluster was accepted as the calculated binding energy. The lowest ligand 
RMSD cluster was usually ranked as the first cluster; the clusters that were ranked as a second cluster are marked with (*). Average N values from 
docking results of all MD simulation time scales are lower than an average N value from protein-rigid docking, indicating that the ligands bind to the 
binding pocket of the MD simulated structures with higher specificity.BMC Structural Biology 2003, 3 http://www.biomedcentral.com/1472-6807/3/2
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Docking runs were performed using the Larmarckian ge-
netic algorithm (LGA) [4] as previously described [63,64]
with some modifications of the docking parameters. The
LGA describes the relationship between the protein and
the ligand by the translation, orientation, and conforma-
tion of the ligand. These "state variables" are the ligand's
genotype, and the resulting atomic coordinates together
with the interaction and intermolecular energies are the
ligand's phenotype. The environmental adaptation of the
ligand's phenotype was reverse transcribed into its geno-
type and became heritable traits.
Docking began with a population of random ligand con-
formations in random orientations and at random trans-
lations. Each docking experiment was derived from 100
different runs that was set to terminate after a maximum
of 1,500,000 energy evaluations or 27,000 generations,
yielding 100 docked conformations. The population size
was set to 50. The elitism number, the rate of gene muta-
tion and the rate of gene crossover were 1, 0.02 and 0.8 re-
spectively. A pseudo-Solis and Wets local search was then
used to minimize energy of the population. The probabil-
ity that docking solution in the population would under-
go a local search was set to 0.06 and the constraint was set
to a maximum of 300 iterations per search. The maximum
number of successes or failures before changing the size of
local search space (rho) were both set to 4. The starting
conformations of the ligand were set to random positions.
Translations were set to have a maximum limit of 2 Å/step
and the orientation step size for the angular component
and the torsions had a maximum limit at 50 degrees/step.
At the end of a docking job with multiple runs, AutoDock
performed cluster analysis. Docking solutions with ligand
all-atom RMSDs within 1.0 Å of each other were clustered
together and ranked by the lowest energy representative.
The lowest-energy solution of the lowest ligand all-atom
RMSD cluster was accepted as the calculated binding
energy.
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